Skip to main content
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc. — Investor Relations & Filings

Ticker · EBS ISIN · US29089Q1058 LEI · 549300YW6TUOX8BE5103 US Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2026-04-30 Earnings Release
Country US United States of America
Listing US EBS

About Emergent BioSolutions Inc.

https://emergentbiosolutions.com/

Emergent BioSolutions Inc. is a life sciences company specializing in solutions for public health threats. The company develops, manufactures, and delivers medical countermeasures for national security and public health preparedness, addressing threats such as anthrax, smallpox, botulism, and Ebola. In addition to its biodefense portfolio, Emergent provides commercial products for endemic health crises, notably the opioid epidemic. The company also offers contract development and manufacturing services through strategic partnerships, leveraging its specialized capabilities to support biopharmaceutical innovators, governments, and non-governmental organizations.

Recent filings

Filing Released Lang Actions
8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 30, 2026, by Emergent BioSolutions Inc. It announces the issuance of a press release with financial results for the quarter ended March 31, 2026, and mentions an upcoming earnings conference call with presentation slides. The document itself is a current report providing updates on recent events, including financial results and a conference call, but does not contain the full financial statements or detailed financial analysis. The press release and earnings call slides are attached as exhibits, indicating this filing is primarily an announcement of earnings results and related disclosures. According to the filing definitions, an initial announcement of quarterly financial results with key highlights corresponds to an Earnings Release (ER). The document length is under 5,000 characters, and it includes the press release and call slides as exhibits, consistent with an Earnings Release filing rather than a full Interim/Quarterly Report (IR). Therefore, the appropriate classification is Earnings Release (ER).
2026-04-30 English
8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated April 29, 2026. It reports the submission of matters to a vote of security holders at the company's 2026 annual meeting, including detailed voting results for director elections, auditor ratification, executive compensation advisory vote, and stock incentive plan amendment. The document is not a full annual report or financial statement but a report on voting results from the annual meeting. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 5444 characters, which is sufficient to contain detailed voting results rather than just an announcement of a report. Therefore, the correct classification is DVA with high confidence.
2026-04-30 English
SCHEDULE 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)
Major Shareholding Notification
2026-03-26 English
ARS - Emergent BioSolutions Inc. (0001367644) (Filer)
Annual Report FY 2025
2026-03-20 English
DEFA14A - Emergent BioSolutions Inc. (0001367644) (Filer)
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled 'SCHEDULE 14A' and is identified as a 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934.' It is marked as 'Definitive Additional Materials' related to a proxy statement filing. Proxy statements are materials sent to shareholders to provide information and request votes for meetings. The document does not contain financial statements or detailed financial analysis but is related to shareholder voting information. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is short (1998 characters), consistent with proxy materials rather than full reports.
2026-03-20 English
DEF 14A - Emergent BioSolutions Inc. (0001367644) (Filer)
Proxy Solicitation & Information Statement
2026-03-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.